OBJECTIVES: The differences in treatment patterns for metastatic colorectal cancer (mCRC) patients have not been extensively studied in Chinese practice setting.This study evaluated the treatment patterns of cetuximab in the real-world setting in China. METHODS: This study used administrative data from the Qingdao City and Zhejiang Province from 2015 to 2016. All patients with metastatic colorectal cancer (mCRC) treated with cetuximab were included.The outcome of cetuximab was monitored during this period, and the combining regimens and agents were analyzed for 2 years following the initiation of chemotherapy RESULTS: There are 105 cases that received cetuximab treatment. The median time of adding cetuximab is 359 days (quartile range: 85.0 – 571.0 days). When health insurance or patients assistant program was provided, frequency of receiving cetuximab treatment at the initiating chemotherapy would be increased. The combination regimens were FFOLFIRI(49.10%), Other(17.10%),Capecitabine(17.6%), FOLFOX(10.50%), Capecitabine+Oxaliplatin(6.30%), mFOLFOX6(1.80%),FOLFOXIRI(0.60%). There are 26 cases that received two combing regimens , including 8 cases with the regimens switched from FOLFIRI to Capecitabine, 3 cases from FOLFIRI to FOLFOX.There are 6 cases that received three combing regimens CONCLUSIONS: Our findings suggest that patients with mCRC could gain health benefits from the Chinese health insurance or patients assistant program covering cetuximab. The combing regimens were varied in Chinese practice, which should be evaluated for there their difference in efficacy and safety.